Resveratrol prevents doxorubicin-induced cardiotoxicity in H9c2 cells through the inhibition of endoplasmic reticulum stress and the activation of the Sirt1 pathway

International Journal of Molecular Medicine

Volumn 36, Issue 3, 2015, Pages 873-880

  Lou, Yu ^a   Wang, Zhen ^a   Xu, Yi ^a   Zhou, Ping ^a   Cao, Junxian ^a   Li, Yuanshi ^a   Chen, Yeping ^a   Sun, Junfeng ^a   Fu, Lu ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Doxorubicin; Endoplasmic reticulum stress; Resveratrol; Sirt1 pathway

Indexed keywords

COMPLEMENTARY DNA; DOXORUBICIN; RESVERATROL; RNA; SIRTUIN 1; ANTINEOPLASTIC ANTIBIOTIC; ANTIOXIDANT; SIRT1 PROTEIN, RAT; STILBENE DERIVATIVE;

ANIMAL CELL; ARTICLE; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CELL DEATH; CELL SURVIVAL; CELL VIABILITY ASSAY; CONTROLLED STUDY; DRUG INDUCED DISEASE; ENDOPLASMIC RETICULUM STRESS; HEART FAILURE; HEART MUSCLE CELL; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANIMAL; CELL LINE; DRUG EFFECTS; METABOLISM; MYOBLAST; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIOXIDANTS; CARDIOTOXICITY; CELL LINE; CELL SURVIVAL; DOXORUBICIN; ENDOPLASMIC RETICULUM STRESS; MYOBLASTS; RATS; SIGNAL TRANSDUCTION; SIRTUIN 1; STILBENES;

EID: 84938072752     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2015.2291     Document Type: Article

References (61)

1. Muggia FM and Green MD: New anthracycline antitumor antibiotics. Crit Rev Oncol Hematol 11: 43-64, 1991.
2. Weiss RB: The anthracyclines: Will we ever find a better doxorubicin? Semin Oncol 19: 670-686, 1992.
3. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE and Sanders SP: Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. New Engl J Med 324: 808-815, 1991.
4. Shan K, Lincoff AM and Young JB: Anthracycline-induced cardiotoxicity. Ann Intern Med 125: 47-58, 1996.
5. Doroshow JH: Effect of anthracycline antibiotics on oxygen radical formation in rat heart. Cancer Res 43: 460-472, 1983.
6. Olson RD and Mushlin PS: Doxorubicin cardiotoxicity: Analysis of prevailing hypotheses. FASEB J 4: 3076-3086, 1990.
7. Danz ED, Skramsted J, Henry N, Bennett JA and Keller RS: Resveratrol prevents doxorubicin cardiotoxicity through mitochondrial stabilization and the Sirt1 pathway. Free Radic Biol Med 46: 1589-1597, 2009.
8. Dirks-Naylor AJ: The role of autophagy in doxorubicin-induced cardiotoxicity. Life Sci 93: 913-916, 2013.
9. Rasheva VI and Domingos PM: Cellular responses to endoplasmic reticulum stress and apoptosis. Apoptosis 14: 996-1007, 2009.
10. Oyadomari S and Mori M: Roles of CHOP/GADD153 in endoplasmic reticulum stress. Cell Death Differ 11: 381-389, 2004.
11. Zinszner H, Kuroda M, Wang X, Batchvarova N, Lightfoot RT, Remotti H, Stevens JL and Ron D: CHOP is implicated in programmed cell death in response to impaired function of the endoplasmic reticulum. Genes Dev 12: 982-995, 1998.
12. Ron D and Walter P: Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol 8: 519-529, 2007.
13. Schröder M: The unfolded protein response. Mol Biotechnol 34: 279-290, 2006.
14. Zu K, Bihani T, Lin A, Park YM, Mori K and Ip C: Enhanced selenium effect on growth arrest by Bip/GRP78 knockdown in p53-null human prostate cancer cells. Oncogene 25: 546-554, 2006.
15. Xu C, Bailly-Maitre B and Reed JC: Endoplasmic reticulum stress: cell life and death decisions. J Clin Invest 115: 2656-2664, 2005.
16. Liu J, Mao W, Iwai C, Fukuoka S, Vulapalli R, Huang H, Wang T, Sharma VK, Sheu SS, Fu M and Liang CS: Adoptive passive transfer of rabbit beta1-adrenoceptor peptide immune cardiomyopathy into the Rag2-/- mouse: Participation of the ER stress. J Mol Cell Cardiol 44: 304-314, 2008.
17. Mandl J and Bánhegyi G: Endoplasmic reticulum stress - common pathomechanism of different diseases? Orv Hetil 148: 1779-1785, 2007 (In Hungarian).
18. Chua CC, Liu X, Gao J, Hamdy RC and Chua BH: Multiple actions of pifithrin-alpha on doxorubicin-induced apoptosis in rat myoblastic H9c2 cells. Am J Physiol Heart Circ Phys 290: H2606-H2613, 2006.
19. Lai HC, Yeh YC, Ting CT, Lee WL, Lee HW, Wang LC, Wang KY, Lai HC, Wu A and Liu TJ: Doxycycline suppresses doxorubicin-induced oxidative stress and cellular apoptosis in mouse hearts. Eur J Pharmacol 644: 176-187, 2010.
20. Reeve JL, Szegezdi E, Logue SE, Ní Chonghaile T, O'Brien T, Ritter T and Samali A: Distinct mechanisms of cardiomyocyte apoptosis induced by doxorubicin and hypoxia converge on mitochondria and are inhibited by Bcl-xL. J Cell Mol Med 11: 509-520, 2007.
21. Lu M, Merali S, Gordon R, Jiang J, Li Y, Mandeli J, Duan X, Fallon J and Holland JF: Prevention of Doxorubicin cardiopathic changes by a benzyl styryl sulfone in mice. Genes Cancer 2: 985-992, 2011.
22. Das DK, Sato M, Ray PS, Maulik G, Engelman RM, Bertelli AA and Bertelli A: Cardioprotection of red wine: Role of polyphenolic antioxidants. Drugs Exp Clin Res 25: 115-120, 1999.
23. Orallo F, Alvarez E, Camiña M, Leiro JM, Gómez E and Fernández P: The possible implication of trans-Resveratrol in the cardioprotective effects of long-term moderate wine consumption. Mol Pharmacol 61: 294-302, 2002.
24. Sabe AA, Sadek AA, Elmadhun NY, Dalal RS, Robich MP, Bianchi C and Sellke FW: Investigating the effects of resveratrol on chronically ischemic myocardium in a Swine model of metabolic syndrome: A proteomics analysis. J Med Food 18: 60-66, 2015.
25. Gu XS, Wang ZB, Ye Z, Lei JP, Li L, Su DF and Zheng X: Resveratrol, an activator of SIRT1, upregulates AMPK and improves cardiac function in heart failure. Genet Mol Res 13: 323-335, 2014.
26. Dolinsky VW, Rogan KJ, Sung MM, Zordoky BN, Haykowsky MJ, Young ME, Jones LW and Dyck JR: Both aerobic exercise and resveratrol supplementation attenuate doxorubicin-induced cardiac injury in mice. Am J Physiol Endocrinol Metab 305: E243-E253, 2013.
27. Brachmann CB, Sherman JM, Devine SE, Cameron EE, Pillus L and Boeke JD: The SIR2 gene family, conserved from bacteria to humans, functions in silencing, cell cycle progression, and chromosome stability. Genes Dev 9: 2888-2902, 1995.
28. Bitterman KJ, Anderson RM, Cohen HY, Latorre-Esteves M and Sinclair DA: Inhibition of silencing and accelerated aging by nicotinamide, a putative negative regulator of yeast sir2 and human SIRT1. J Biol Chem 277: 45099-45107, 2002.
29. Blander G and Guarente L: The Sir2 family of protein deacetylases. Ann Rev Biochem 73: 417-435, 2004.
30. Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, Lin Y, Tran H, Ross SE, Mostoslavsky R, Cohen HY, et al: Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 303: 2011-2015, 2004.
31. Chen CJ, Yu W, Fu YC, Wang X, Li JL and Wang W: Resveratrol protects cardiomyocytes from hypoxia-induced apoptosis through the SIRT1-FoxO1 pathway. Biochem Biophys Res Commun 378: 389-393, 2009.
32. Hsu CP, Zhai P, Yamamoto T, Maejima Y, Matsushima S, Hariharan N, Shao D, Takagi H, Oka S and Sadoshima J: Silent information regulator 1 protects the heart from ischemia/reperfusion. Circulation 122: 2170-2182, 2010.
33. Alcendor RR, Gao S, Zhai P, Zablocki D, Holle E, Yu X, Tian B, Wagner T, Vatner SF and Sadoshima J: Sirt1 regulates aging and resistance to oxidative stress in the heart. Circ Res 100: 1512-1521, 2007.
34. Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, Wood JG, Zipkin RE, Chung P, Kisielewski A, Zhang LL, et al: Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425: 191-196, 2003.
35. Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, Messadeq N, Milne J, Lambert P, Elliott P, et al: Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 127: 1109-1122, 2006.
36. Wood JG, Rogina B, Lavu S, Howitz K, Helfand SL, Tatar M and Sinclair D: Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature 430: 686-689, 2004.
37. Liu LQ, Fan ZQ, Tang YF and Ke ZJ: The resveratrol attenuates ethanol-induced hepatocyte apoptosis via inhibiting ER-related caspase-12 activation and PDE activity in vitro. Alcohol Clin Exp Res 38: 683-693, 2014.
38. Li YG, Zhu W, Tao JP, Xin P, Liu MY, Li JB and Wei M: Resveratrol protects cardiomyocytes from oxidative stress through SIRT1 and mitochondrial biogenesis signaling pathways. Biochem Biophys Res Commun 438: 270-276, 2013.
39. Chen B, Xue J, Meng X, Slutzky JL, Calvert AE and Chicoine LG: Resveratrol prevents hypoxia-induced arginase II expression and proliferation of human pulmonary artery smooth muscle cells via Akt-dependent signaling. Am J Physiol Lung Cell Mol Physiol 307: L317-L325, 2014.
40. Arafa MH, Mohammad NS, Atteia HH and Abd-Elaziz HR: Protective effect of resveratrol against doxorubicin-induced cardiac toxicity and fibrosis in male experimental rats. J Physiol Biochem 70: 701-711, 2014.
41. Huang JP, Huang SS, Deng JY, Chang CC, Day YJ and Hung LM: Insulin and resveratrol act synergistically, preventing cardiac dysfunction in diabetes, but the advantage of resveratrol in diabetics with acute heart attack is antagonized by insulin. Free Radic Biol Med 49: 1710-1721, 2010.
42. Yang DL, Zhang HG, Xu YL, Gao YH, Yang XJ, Hao XQ and Li XH: Resveratrol inhibits right ventricular hypertrophy induced by monocrotaline in rats. Clin Exp Pharmacol Physiol 37: 150-155, 2010.
43. Chen YR, Yi FF, Li XY, Wang CY, Chen L, Yang XC, Su PX and Cai J: Resveratrol attenuates ventricular arrhythmias and improves the long-term survival in rats with myocardial infarction. Cardiovasc Drugs Ther 22: 479-485, 2008.
44. Wang XY, Yang CT, Zheng DD, Mo LQ, Lan AP, Yang ZL, Hu F, Chen PX, Liao XX and Feng JQ: Hydrogen sulfide protects H9c2 cells against doxorubicin-induced cardiotoxicity through inhibition of endoplasmic reticulum stress. Mol Cell Biochem 363: 419-426, 2012.
45. Zhang C, Feng Y, Qu S, Wei X, Zhu H, Luo Q, Liu M, Chen G and Xiao X: Resveratrol attenuates doxorubicin-induced cardiomyocyte apoptosis in mice through SIRT1-mediated deacetylation of p53. Cardiovasc Res 90: 538-545, 2011.
46. Ueno M, Kakinuma Y, Yuhki K, Murakoshi N, Iemitsu M, Miyauchi T and Yamaguchi I: Doxorubicin induces apoptosis by activation of caspase-3 in cultured cardiomyocytes in vitro and rat cardiac ventricles in vivo. J Pharmacol Sci 101: 151-158, 2006.
47. Sishi BJ, Loos B, van Rooyen J and Engelbrecht AM: Doxorubicin induces protein ubiquitination and inhibits proteasome activity during cardiotoxicity. Toxicology 309: 23-29, 2013.
48. Lv XC and Zhou HY: Resveratrol protects H9c2 embryonic rat heart derived cells from oxidative stress by inducing autophagy: Role of p38 mitogen-activated protein kinase. Can J Physiol Pharmacol 90: 655-662, 2012.
49. Lekli I, Szabo G, Juhasz B, Das S, Das M, Varga E, Szendrei L, Gesztelyi R, Varadi J, Bak I, et al: Protective mechanisms of resveratrol against ischemia-reperfusion-induced damage in hearts obtained from Zucker obese rats: The role of GLUT-4 and endothelin. Am J Physiol Heart Circ Physiol 294: H859-H866, 2008.
50. Das S, Falchi M, Bertelli A, Maulik N and Das DK: Attenuation of ischemia/reperfusion injury in rats by the anti-inflammatory action of resveratrol. Arzneimittelforschung 56: 700-706, 2006.
51. Goh SS, Woodman OL, Pepe S, Cao AH, Qin C and Ritchie RH: The red wine antioxidant resveratrol prevents cardiomyocyte injury following ischemia-reperfusion via multiple sites and mechanisms. Antioxid Redox Signal 9: 101-113, 2007.
52. Hung LM, Su MJ, Chu WK, Chiao CW, Chan WF and Chen JK: The protective effect of resveratrols on ischaemia-reperfusion injuries of rat hearts is correlated with antioxidant efficacy. Br J Pharmacol 135: 1627-1633, 2002.
53. El-Mowafy AM and White RE: Resveratrol inhibits MAPK activity and nuclear translocation in coronary artery smooth muscle: Reversal of endothelin-1 stimulatory effects. FEBS Lett 451: 63-67, 1999.
54. Yamamoto H, Schoonjans K and Auwerx J: Sirtuin functions in health and disease. Mol Endocrinol 21: 1745-1755, 2007.
55. Becatti M, Taddei N, Cecchi C, Nassi N, Nassi PA and Fiorillo C: SIRT1 modulates MAPK pathways in ischemic-reperfused cardiomyocytes. Cell Mol Life Sci 69: 2245-2260, 2012.
56. Ungvari Z, Labinskyy N, Mukhopadhyay P, Pinto JT, Bagi Z, Ballabh P, Zhang C, Pacher P and Csiszar A: Resveratrol attenuates mitochondrial oxidative stress in coronary arterial endothelial cells. Am J Physiol Heart Circ Physiol 297: H1876-H1881, 2009.
57. Hsu CP, Odewale I, Alcendor RR and Sadoshima J: Sirt1 protects the heart from aging and stress. Biol Chem 389: 221-231, 2008.
58. Viswanathan M, Kim SK, Berdichevsky A and Guarente L: A role for SIR-2.1 regulation of ER stress response genes in determining C. elegans life span. Dev Cell 9: 605-615, 2005.
59. Li Y, Xu S, Giles A, Nakamura K, Lee JW, Hou X, Donmez G, Li J, Luo Z, Walsh K, et al: Hepatic overexpression of SIRT1 in mice attenuates endoplasmic reticulum stress and insulin resistance in the liver. FASEB J 25: 1664-1679, 2011.
60. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, Fong HH, Farnsworth NR, Kinghorn AD, Mehta RG, et al: Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275: 218-220, 1997.
61. Rezk YA, Balulad SS, Keller RS and Bennett JA: Use of resveratrol to improve the effectiveness of cisplatin and doxorubicin: Study in human gynecologic cancer cell lines and in rodent heart. Am J Obstet Gynecol 194: e23-e26, 2006.